HIV Drugs Market to Reach Valuation of USD 40.3 Billion by 2028 – Increasing Number of New Product Launches and Rising Drug Approvals Drives the Market

In terms of revenue, the Global HIV Drugs Market is expected to reach by 2028, growing at a CAGR (Compound Annual Growth Rate) of 3.7% from 2022 to 2028.

One of the most severe and persistent illnesses brought on by the human immunodeficiency virus is regarded to be acquired immune deficiency syndrome (AIDS) (HIV). It is a viral infection that spreads through contact with blood, semen, breast milk, and other agents that have HIV infected them. HIV infection rates are increasing dramatically. The World Health Organization (WHO) estimates that 33.0 million people worldwide are HIV-positive. People are increasingly more conscious of this, which has increased the number of testing processes. High-potency HIV drugs are now in high demand for the treatment and management of the condition as a result of this. The market is projected to develop due to the rising patient population and the introduction of new products. The market is growing due to extensive research and development, government-sponsored awareness campaigns, the introduction of new products, and growing market penetration by leading corporations in developing nations.

The global healthcare goods import and export have been hampered by the COVID-19 epidemic. Because of the disruption and volatility in the medicine supply, the pandemic has negatively affected this industry's growth. Also, the demand for antiretroviral and antibiotic drugs has decreased globally due to the decline in new patient prescriptions in the United States, Europe, and other COVID-affected areas and nations. Most businesses have noted the epidemic's negative effect on the sales of HIV/AIDS medications. For instance, Gilead Sciences Inc., one of the top producers of antiretroviral drugs, said that the lower sales of Truvada had affected the sales of its HIV treatments. Similar to this, due to severe lockdown measures implemented in several European countries, Theratechnologies Inc. observed a decline in the sales of HIV medications like Trogarzo in most COVID afflicted countries, which includes regions like the European Union.

Moreover, ViiV Healthcare said that in the second quarter of 2020, sales of HIV medications fell sharply. Nonetheless, the demand for HIV/AIDS drugs grew in the fourth quarter of 2020. Overall, during the pandemic, this market grew relatively slowly.

Key Highlights from the Report

· Based on the Drug Classes, the combination HIV medicines segment is anticipated to dominate the HIV Drugs market with the largest market share in the forecast period. The market is expected to be dominated by HIV combo medications. Its dominance is attributable to the rising demand for this medicine class due to improved outcomes in treating co-infections and HIV. Also, the most cutting-edge technology for the treatment of HIV infections is included in this pharmacological class.

· Based on the Distribution Channels, the hospital pharmacies segment accounted for the maximum CAGR during the forecast period, increasing patients seeking HIV treatment at hospitals. Furthermore, the segmental development would be supported by hospital pharmacists' rising prescription antiretroviral medicine sales for the treatment of HIV.

· In terms of region, North America held the major market share in 2022 and is likely to be the most gainful market in the future. The increasing prevalence of HIV infection in the U.S. is aiding this market expansion.

Market Dynamics

The creation of antiretroviral therapy as a long-acting suppression (ATLAS) and the first long-acting injectable formulation are two trends in the global market. As a result of a significant number of patients now having access to the once-monthly dosage, the new ATLAS regimens are a practical treatment choice, and doctors believe that compliance rates will rise as a result.

The new comprehensive long-acting regimen, which combines cabotegravir and rilpivirine, can be used as an alternative to the already available HIV medications. In comparison to the HIV medications that are most frequently administered, the new injectable formulation has now made it onto the world market and raised the bar for healthcare. This new therapy cuts dosing days from 365 to 12 per year. The new medication contains the ViiV Healthcare product Cabenuva (cabotegravir, rilpivirine). The Cabenuva medication was given FDA approval in January 2020. During the anticipated time, the market's expansion will be diversified by these future new trends.

Several drug advancements have recently resulted from the increased focus on HIV drug research and development (R&D). Gilead Sciences, ViiV Healthcare, and Boehringer Ingelheim International GmbH are three significant corporations in these investment projects. Also, many businesses participate in global launches of new drugs and strategic alliances. For instance, Cabenuva, the first and only full long-acting regimen combination medication for HIV therapy, was approved by the U.S. FDA in January 2021. Moreover, in September 2019, Merck Sharp & Dohme Corp., a Merck & Co., Inc. division, got FDA approval in the United States for the combination medicines PIFELTRO and DELSTRIGO. As a result, adults with HIV-1 can be treated with these medications.

One of the key reasons projected to fuel market expansion is the rising prevalence of HIV/AIDS, particularly in Africa. The World Health Organization (WHO) estimates that 33.0 million persons worldwide are HIV-positive and that 1.7 million new cases of HIV infection were recorded in 2019. In addition, the Joint United Nations Programme on HIV/AIDS (UNAIDS) estimates that in 2019 2.2 million people were living with HIV in Western and Central Europe and North America, 20.7 million in Eastern and Southern Africa, 5.8 million in Asia Pacific, and an additional 4.9 million people in Western and Central Africa. The demand for antiretroviral (ARV) medications is extremely high due to the vast patient population spread across several locations. The government is also making efforts to make it easier for HIV sufferers to receive diagnosis and treatment. The market for medications to treat HIV/AIDS is expected to grow.

North America HIV Drugs market is expected to witness a noteworthy development with a significant growth rate over the analysis period. The rising prevalence of HIV infection among Americans is to blame for this region's dominance. The Centers for Disease Control (CDC) estimated in 2021 that at the end of 2018, about 1.2 million people were living with HIV. Such a large patient group greatly increases the need for HIV medications. The population's awareness is another element influencing the progress of the region. Also, the existence of major players who provide cutting-edge HIV medications to treat HIV infection will further accelerate market expansion.

The Global HIV Drugs Market is Segmented as follows

• Drug Classes
  • Integrase Inhibitors
  • Non- Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
  • Combination HIV Medicines
  • Other Drug Classes
• Distribution Channels
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Other Distribution Channels
• Region
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa

List of the Key Players of the Global HIV Drugs Market is

ViiV Healthcare (U.S.), Gilead Sciences Inc. (U.S.), Glaxo Smith Kline PLC (U.K.), Merck Sharp & Dohme Corp. (France), Bristol-Myers Squibb Company (U.S.), Janssen Pharmaceuticals Inc. (Johnson & Johnson) (Belgium), Boehringer Ingelheim International GmbH (Germany), AbbVie Inc. (U.S.), Genentech Inc. (F. Hoffmann-La Roche AG) (U.S.), Mylan N.V. (U.S.)

The Global HIV Drugs Market Scope can be Tabulated as below